The US Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee on 10 December will be tasked with reviewing the available efficacy and safety data on Pfizer Inc./BioNTech SE’s COVID-19 vaccine.
Pfizer's COVID-19 Vaccine Brings Gaps In Efficacy And Safety Data To US FDA Panel
Agency details a host of unknowns regarding the benefits and risks of the first COVID-19 vaccine to reach the advisory committee stage, including uncertainties about duration of protection, effectiveness against transmission and vaccine-enhanced disease.
